Dermal Spray Formulation of Meloxicam
DOI:
https://doi.org/10.61841/pf7m4r37Keywords:
Inflammation, edema, swelling, parenteral route, meloxicam, NSAID, dermal, meglumineAbstract
Pain and inflammation, often seen in the form of “edema” (swelling) is one of the most common conditions which affect the animals due to injuries. Inflammation is a localised protective response stimulated by injury or destruction of tissues, which serves to dilute, destroy or wall off both the injurious agent and the injured tissue. The classic signs of inflammation are heat, redness, pain, swelling and loss of function. Numerous numbers of treatments via oral and parenteral route of administration are available for treating the conditions of pain and inflammation in animals. Though meloxicam demonstrated good oral bioavailability (76%) in cattles; however; oral and parenteral administration of meloxicam are associated with GI distress, vomiting, soft stools, diarrhea, in appetence and suboptimal concentration at the site of inflammation. NSAIDs skin delivery offers a number of benefits over the oral route associated with potential side effects. Therefore, the aim of this study is to provide a dermal spray formulation of a meglumine salt of meloxicam for the treatment of pain and inflammation in cattles. Meloxicam spray was then estimated with respect to different physicochemical parameters such as pH, drug content and Homogeneity.
Downloads
References
[1] G. Jacobs, “Meloxicam,” in The Essence of Analgesia and Analgesics, 2010.
[2] T. Lee et al., “Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous
thromboembolism in knee osteoarthritis patients: A UK population-based case-control study,” Rheumatol.
(United Kingdom), 2016.
[3] R. M. Khalil, A. A. El-bary, M. A. Kassem, M. M. Ghorab, and M. B. Ahmed, “Solid lipid nanoparticles
for topical delivery of Meloxicam: development and In Vitro characterization,” Eur. Sci. J., 2013.
[4] S. Mohammadi-Samani, G. Yousefi, F. Mohammadi, and F. Ahmadi, “Meloxicam transdermal delivery:
Effect of eutectic point on the rate and extent of skin permeation,” Iran. J. Basic Med. Sci., 2014.
[5] M. A. Ruiz Martinez, J. López-Viota Gallardo, M. M. de Benavides, J. de Dios GarcíaLópez-Duran, and V.
Gallardo Lara, “Rheological behavior of gels and meloxicam release,” Int. J. Pharm., 2007.
[6] Khalil, A. A. El-Bary, M. A. Kassem, M. M. Ghorab, and M. Basha, “Influence of formulation parameters
on the physicochemical properties of meloxicam-loaded solid lipid nanoparticles,” Egypt. Pharm. J., 2013.
[7] M. B. Walton, E. C. Cowderoy, B. Wustefeld-Janssens, B. D. X. Lascelles, and J. F. Innes, “Mavacoxib
and meloxicam for canine osteoarthritis: A randomised clinical comparator trial,” Vet. Rec., 2014.
[8] M. O. E. Hilário, M. T. Terreri, and C. A. Len, “Nonsteroidal anti-inflammatory drugs: Cyclooxygenase 2
inhibitors,” Jornal de Pediatria. 2006.
[9] H. Schlegel, Microbiologia general. 1997.
[10] B. K. Abdul Rasool, R. H. Gareeb, S. A. Fahmy, and A. A. Abdul Rasool, “Meloxicam β-
Cyclodextrin Transdermal Gel: Physicochemical Characterization and In Vitro Dissolution and Diffusion
Studies,” Curr. Drug Deliv., 2011.
[11] J. A. Balko, M. K. Watson, M. G. Papich, L. P. Posner, and S. K. Chinnadurai, “Plasma Concentrations of
Ketoprofen and Meloxicam after Subcutaneous and Topical Administration in the Smoky Jungle Frog
(Leptodactyluspentadactylus),” J. Herpetol. Med. Surg., 2019.
[12] M. M. Nitalikar and D. M. Sakarkar, “Formulation and evaluation of topical gel of meloxicam with β-
cyclodextrin complex,” Research Journal of Pharmacy and Technology. 2013.
[13] M. A. Saleem, S. Bala, Liyakat, and A. Aeajaz, “Effect of different carriers on in vitro permeation of
meloxicam through rat skin,” Indian J. Pharm. Sci., 2010.
[14] C. B. Winder, S. J. LeBlanc, D. B. Haley, K. D. Lissemore, M. A. Godkin, and T. F. Duffield, “Clinical
trial of local anesthetic protocols for acute pain associated with caustic paste disbudding in dairy calves,” J.
Dairy Sci., 2017.
[15] S. Fattahpour, M. Shamanian, N. Tavakoli, M. Fathi, S. R. Sheykhi, and S. Fattahpour, “Design and
optimization of alginate-chitosan-pluronic nanoparticles as a novel meloxicam drug delivery system,” J.
Appl. Polym. Sci.,2015
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
